Christina Aquilante
Concepts (345)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pharmacogenetics | 28 | 2024 | 153 | 6.520 |
Why?
| Pharmacogenomic Testing | 13 | 2022 | 54 | 4.490 |
Why?
| Thiazolidinediones | 8 | 2016 | 143 | 2.860 |
Why?
| Aryl Hydrocarbon Hydroxylases | 10 | 2014 | 41 | 2.530 |
Why?
| Heart Transplantation | 8 | 2021 | 672 | 2.310 |
Why?
| Polymorphism, Genetic | 17 | 2019 | 632 | 2.260 |
Why?
| Precision Medicine | 9 | 2024 | 356 | 1.660 |
Why?
| Polymorphism, Single Nucleotide | 10 | 2021 | 2022 | 1.530 |
Why?
| Hypoglycemic Agents | 11 | 2020 | 1008 | 1.520 |
Why?
| Health Personnel | 4 | 2021 | 578 | 1.490 |
Why?
| Cytochrome P-450 CYP2C19 | 6 | 2024 | 25 | 1.470 |
Why?
| Decision Support Systems, Clinical | 2 | 2024 | 179 | 1.360 |
Why?
| Transplant Recipients | 5 | 2021 | 144 | 1.310 |
Why?
| Blood Pressure | 8 | 2020 | 1536 | 1.240 |
Why?
| Organ Transplantation | 2 | 2020 | 161 | 1.190 |
Why?
| Metabolic Syndrome | 4 | 2016 | 323 | 1.160 |
Why?
| Cytochrome P-450 CYP2D6 | 4 | 2022 | 25 | 1.100 |
Why?
| Graft Rejection | 2 | 2021 | 533 | 1.040 |
Why?
| Pharmacists | 3 | 2022 | 235 | 1.000 |
Why?
| Genotype | 17 | 2024 | 1843 | 0.880 |
Why?
| Cytochrome P-450 CYP3A | 6 | 2016 | 62 | 0.820 |
Why?
| Gemfibrozil | 2 | 2013 | 10 | 0.810 |
Why?
| Adiponectin | 2 | 2016 | 213 | 0.790 |
Why?
| Sulfonylurea Compounds | 3 | 2018 | 44 | 0.780 |
Why?
| Leukopenia | 1 | 2021 | 27 | 0.780 |
Why?
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2021 | 16 | 0.780 |
Why?
| Hypolipidemic Agents | 2 | 2013 | 87 | 0.760 |
Why?
| Mycophenolic Acid | 1 | 2021 | 81 | 0.750 |
Why?
| Desogestrel | 5 | 2021 | 40 | 0.730 |
Why?
| Platelet Aggregation Inhibitors | 1 | 2024 | 400 | 0.730 |
Why?
| Hypertension | 3 | 2020 | 1063 | 0.730 |
Why?
| Organic Anion Transporters | 2 | 2011 | 15 | 0.730 |
Why?
| Biological Specimen Banks | 2 | 2024 | 101 | 0.720 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2013 | 374 | 0.690 |
Why?
| Adult | 41 | 2022 | 30814 | 0.690 |
Why?
| Middle Aged | 38 | 2021 | 27080 | 0.670 |
Why?
| Humans | 74 | 2024 | 115890 | 0.660 |
Why?
| Prescription Drugs | 2 | 2020 | 116 | 0.650 |
Why?
| Cytochrome P-450 CYP2C8 | 7 | 2014 | 15 | 0.640 |
Why?
| Cardiologists | 1 | 2018 | 41 | 0.640 |
Why?
| Physicians | 3 | 2021 | 774 | 0.620 |
Why?
| Dipeptidyl-Peptidase IV Inhibitors | 2 | 2021 | 43 | 0.610 |
Why?
| Female | 50 | 2021 | 60076 | 0.600 |
Why?
| Male | 46 | 2021 | 56123 | 0.590 |
Why?
| HIV Protease Inhibitors | 4 | 2016 | 64 | 0.590 |
Why?
| Academic Medical Centers | 1 | 2020 | 415 | 0.580 |
Why?
| Ritonavir | 4 | 2012 | 72 | 0.570 |
Why?
| Heart Failure | 4 | 2017 | 1959 | 0.560 |
Why?
| Polypharmacy | 1 | 2017 | 74 | 0.550 |
Why?
| Warfarin | 3 | 2008 | 136 | 0.540 |
Why?
| Lectins | 1 | 2016 | 47 | 0.530 |
Why?
| Attitude of Health Personnel | 2 | 2020 | 990 | 0.530 |
Why?
| Nonprescription Drugs | 1 | 2016 | 68 | 0.520 |
Why?
| Antiviral Agents | 1 | 2021 | 648 | 0.520 |
Why?
| Tacrolimus | 1 | 2016 | 143 | 0.510 |
Why?
| Medicare | 1 | 2020 | 666 | 0.490 |
Why?
| Cytochrome P-450 Enzyme System | 2 | 2006 | 108 | 0.490 |
Why?
| Contraceptive Agents, Female | 3 | 2020 | 65 | 0.480 |
Why?
| Death, Sudden, Cardiac | 3 | 2021 | 158 | 0.480 |
Why?
| Pediatrics | 2 | 2021 | 986 | 0.460 |
Why?
| Blood Pressure Determination | 1 | 2014 | 123 | 0.450 |
Why?
| Arrhythmias, Cardiac | 3 | 2021 | 275 | 0.450 |
Why?
| Chemokine CXCL5 | 3 | 2012 | 12 | 0.440 |
Why?
| Heptanoic Acids | 1 | 2013 | 60 | 0.430 |
Why?
| Pyrazines | 1 | 2013 | 70 | 0.420 |
Why?
| Diabetes Mellitus, Type 2 | 5 | 2020 | 2090 | 0.410 |
Why?
| Resistin | 2 | 2010 | 12 | 0.400 |
Why?
| Pravastatin | 1 | 2011 | 28 | 0.400 |
Why?
| Cross-Sectional Studies | 8 | 2020 | 4449 | 0.400 |
Why?
| Pharmaceutical Preparations | 3 | 2009 | 169 | 0.400 |
Why?
| Pyrroles | 1 | 2013 | 185 | 0.400 |
Why?
| Triazoles | 1 | 2013 | 131 | 0.400 |
Why?
| Health Knowledge, Attitudes, Practice | 4 | 2021 | 1193 | 0.390 |
Why?
| Dobutamine | 3 | 2008 | 33 | 0.380 |
Why?
| Retrospective Studies | 12 | 2021 | 12616 | 0.370 |
Why?
| Managed Care Programs | 2 | 2022 | 135 | 0.360 |
Why?
| Aged | 17 | 2021 | 19296 | 0.360 |
Why?
| Antidepressive Agents | 2 | 2022 | 195 | 0.360 |
Why?
| Mixed Function Oxygenases | 2 | 2008 | 37 | 0.340 |
Why?
| DNA | 1 | 2016 | 1358 | 0.340 |
Why?
| Drug Interactions | 5 | 2017 | 347 | 0.330 |
Why?
| Chromatography, Liquid | 1 | 2010 | 346 | 0.330 |
Why?
| Young Adult | 13 | 2021 | 10515 | 0.330 |
Why?
| Polymerase Chain Reaction | 3 | 2006 | 1001 | 0.320 |
Why?
| Sulfonamides | 1 | 2011 | 447 | 0.310 |
Why?
| Drug Prescriptions | 4 | 2021 | 241 | 0.310 |
Why?
| Cytokines | 1 | 2016 | 1857 | 0.310 |
Why?
| Health | 1 | 2008 | 74 | 0.310 |
Why?
| Blood Glucose | 3 | 2016 | 1826 | 0.300 |
Why?
| Time Factors | 8 | 2020 | 6186 | 0.300 |
Why?
| Chemokine CCL2 | 1 | 2008 | 106 | 0.300 |
Why?
| Drug Implants | 4 | 2021 | 71 | 0.300 |
Why?
| Heart Rate | 3 | 2008 | 698 | 0.300 |
Why?
| Mass Spectrometry | 1 | 2010 | 661 | 0.290 |
Why?
| Immunosuppressive Agents | 4 | 2021 | 666 | 0.290 |
Why?
| Receptors, Adrenergic, beta | 1 | 2008 | 133 | 0.290 |
Why?
| Matrix Metalloproteinase 8 | 1 | 2006 | 8 | 0.290 |
Why?
| Haplotypes | 5 | 2013 | 472 | 0.290 |
Why?
| Electronic Health Records | 3 | 2024 | 801 | 0.280 |
Why?
| Sequence Analysis, DNA | 4 | 2012 | 733 | 0.280 |
Why?
| Vitamin K Epoxide Reductases | 3 | 2020 | 12 | 0.270 |
Why?
| Metoprolol | 1 | 2006 | 37 | 0.270 |
Why?
| Clinical Laboratory Techniques | 1 | 2006 | 86 | 0.270 |
Why?
| Blood Coagulation Factors | 1 | 2006 | 44 | 0.270 |
Why?
| Autonomic Nervous System | 1 | 2006 | 70 | 0.260 |
Why?
| Models, Biological | 1 | 2013 | 1647 | 0.260 |
Why?
| Prospective Studies | 6 | 2020 | 6266 | 0.260 |
Why?
| Administration, Oral | 4 | 2016 | 731 | 0.260 |
Why?
| Clinical Protocols | 2 | 2017 | 233 | 0.260 |
Why?
| Anticoagulants | 2 | 2008 | 545 | 0.250 |
Why?
| Cross-Over Studies | 3 | 2013 | 437 | 0.250 |
Why?
| Echocardiography | 1 | 2008 | 566 | 0.250 |
Why?
| Genetic Variation | 3 | 2019 | 891 | 0.250 |
Why?
| Echocardiography, Stress | 1 | 2004 | 19 | 0.240 |
Why?
| Polymorphism, Restriction Fragment Length | 1 | 2004 | 65 | 0.240 |
Why?
| Carrier Proteins | 1 | 2008 | 703 | 0.230 |
Why?
| Cohort Studies | 7 | 2021 | 4961 | 0.230 |
Why?
| Adrenergic beta-Antagonists | 1 | 2006 | 293 | 0.230 |
Why?
| Biotransformation | 2 | 2013 | 50 | 0.220 |
Why?
| Metformin | 1 | 2007 | 278 | 0.220 |
Why?
| Cytochrome P-450 CYP2C9 | 4 | 2019 | 18 | 0.220 |
Why?
| Alleles | 6 | 2012 | 814 | 0.220 |
Why?
| Waist Circumference | 2 | 2016 | 123 | 0.220 |
Why?
| Gene Frequency | 4 | 2013 | 507 | 0.210 |
Why?
| Follow-Up Studies | 4 | 2021 | 4446 | 0.210 |
Why?
| Clinical Trials as Topic | 1 | 2006 | 945 | 0.200 |
Why?
| Antimalarials | 2 | 2013 | 24 | 0.200 |
Why?
| Drug Dosage Calculations | 1 | 2020 | 21 | 0.190 |
Why?
| Calcineurin Inhibitors | 1 | 2021 | 59 | 0.190 |
Why?
| Pharmacogenomic Variants | 2 | 2021 | 34 | 0.180 |
Why?
| Antibiotics, Antineoplastic | 1 | 2021 | 114 | 0.180 |
Why?
| Egypt | 1 | 2020 | 10 | 0.180 |
Why?
| Cytomegalovirus | 1 | 2021 | 144 | 0.180 |
Why?
| Atazanavir Sulfate | 3 | 2016 | 41 | 0.180 |
Why?
| Aged, 80 and over | 4 | 2017 | 6437 | 0.180 |
Why?
| Cardiovascular Diseases | 3 | 2024 | 1724 | 0.180 |
Why?
| Area Under Curve | 2 | 2013 | 277 | 0.180 |
Why?
| Hemodynamics | 1 | 2004 | 970 | 0.170 |
Why?
| No-Show Patients | 1 | 2019 | 1 | 0.170 |
Why?
| Menstruation Disturbances | 1 | 2019 | 12 | 0.170 |
Why?
| Colorado | 3 | 2024 | 4122 | 0.170 |
Why?
| Blood Pressure Monitoring, Ambulatory | 1 | 2020 | 61 | 0.170 |
Why?
| United States | 8 | 2021 | 12340 | 0.170 |
Why?
| Lipids | 2 | 2016 | 589 | 0.170 |
Why?
| Brain Chemistry | 1 | 2000 | 116 | 0.170 |
Why?
| Cytochrome P450 Family 3 | 1 | 2019 | 2 | 0.170 |
Why?
| Smoking | 1 | 2006 | 1468 | 0.170 |
Why?
| Body Weight | 2 | 2016 | 872 | 0.160 |
Why?
| Double-Blind Method | 2 | 2016 | 1665 | 0.160 |
Why?
| Oligopeptides | 2 | 2012 | 248 | 0.160 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2013 | 301 | 0.160 |
Why?
| Morphine | 1 | 2000 | 124 | 0.160 |
Why?
| Patients | 1 | 2020 | 164 | 0.160 |
Why?
| Body Mass Index | 3 | 2019 | 1982 | 0.160 |
Why?
| Sitagliptin Phosphate | 2 | 2021 | 30 | 0.160 |
Why?
| Bariatric Surgery | 1 | 2021 | 162 | 0.160 |
Why?
| Child Health Services | 1 | 2020 | 180 | 0.160 |
Why?
| Dose-Response Relationship, Drug | 3 | 2016 | 1868 | 0.160 |
Why?
| Progesterone | 1 | 2019 | 232 | 0.160 |
Why?
| Ventricular Dysfunction | 1 | 2018 | 16 | 0.150 |
Why?
| Psychiatry | 1 | 2020 | 155 | 0.150 |
Why?
| Pyridines | 2 | 2012 | 425 | 0.150 |
Why?
| Apyrase | 1 | 2017 | 14 | 0.150 |
Why?
| Organophosphonates | 2 | 2008 | 91 | 0.140 |
Why?
| Healthy Volunteers | 2 | 2019 | 191 | 0.140 |
Why?
| Depression | 2 | 2022 | 1147 | 0.140 |
Why?
| Circadian Rhythm | 1 | 2020 | 371 | 0.140 |
Why?
| Anti-HIV Agents | 2 | 2016 | 669 | 0.140 |
Why?
| DNA Primers | 3 | 2006 | 513 | 0.140 |
Why?
| Chronic Disease | 2 | 2017 | 1602 | 0.140 |
Why?
| Pyrophosphatases | 1 | 2016 | 22 | 0.140 |
Why?
| Treatment Outcome | 6 | 2021 | 9165 | 0.140 |
Why?
| Cardiology | 1 | 2018 | 260 | 0.130 |
Why?
| GPI-Linked Proteins | 1 | 2016 | 54 | 0.130 |
Why?
| Patient Care | 1 | 2016 | 103 | 0.130 |
Why?
| Adenine | 2 | 2008 | 221 | 0.130 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2017 | 274 | 0.130 |
Why?
| Ribavirin | 1 | 2016 | 89 | 0.130 |
Why?
| HIV Infections | 4 | 2016 | 2469 | 0.130 |
Why?
| Students, Pharmacy | 1 | 2016 | 100 | 0.130 |
Why?
| Metabolic Clearance Rate | 2 | 2013 | 108 | 0.130 |
Why?
| Therapeutics | 1 | 2015 | 12 | 0.130 |
Why?
| Delivery of Health Care | 1 | 2022 | 847 | 0.120 |
Why?
| Education, Pharmacy | 1 | 2016 | 128 | 0.120 |
Why?
| beta-Cyclodextrins | 1 | 2015 | 28 | 0.120 |
Why?
| Voriconazole | 1 | 2015 | 24 | 0.120 |
Why?
| Surgical Procedures, Operative | 1 | 2017 | 210 | 0.120 |
Why?
| Renal Replacement Therapy | 1 | 2015 | 68 | 0.120 |
Why?
| Patient Education as Topic | 1 | 2019 | 686 | 0.120 |
Why?
| Antigens, CD | 1 | 2017 | 442 | 0.120 |
Why?
| Adolescent | 6 | 2021 | 17949 | 0.120 |
Why?
| Diltiazem | 1 | 2014 | 23 | 0.120 |
Why?
| Antifungal Agents | 1 | 2015 | 134 | 0.120 |
Why?
| Reoperation | 1 | 2016 | 526 | 0.120 |
Why?
| Chromosomes, Human, Pair 10 | 1 | 2013 | 19 | 0.120 |
Why?
| Cardiomyopathies | 1 | 2017 | 301 | 0.110 |
Why?
| Kidney Transplantation | 1 | 2019 | 560 | 0.110 |
Why?
| Venous Thromboembolism | 1 | 2017 | 234 | 0.110 |
Why?
| Sirolimus | 1 | 2014 | 192 | 0.110 |
Why?
| Half-Life | 1 | 2013 | 145 | 0.110 |
Why?
| Medication Adherence | 1 | 2017 | 536 | 0.100 |
Why?
| Practice Patterns, Physicians' | 1 | 2020 | 1177 | 0.100 |
Why?
| Liver Transplantation | 1 | 2019 | 830 | 0.100 |
Why?
| Tissue Distribution | 2 | 2014 | 324 | 0.100 |
Why?
| Darunavir | 1 | 2011 | 18 | 0.100 |
Why?
| Lung Transplantation | 1 | 2014 | 245 | 0.100 |
Why?
| Self Care | 1 | 2014 | 354 | 0.100 |
Why?
| Genetic Association Studies | 1 | 2013 | 351 | 0.090 |
Why?
| Prevalence | 1 | 2017 | 2271 | 0.090 |
Why?
| Acquired Immunodeficiency Syndrome | 1 | 2012 | 221 | 0.090 |
Why?
| Insulin Resistance | 2 | 2010 | 1077 | 0.090 |
Why?
| Reverse Transcriptase Inhibitors | 2 | 2008 | 82 | 0.090 |
Why?
| Patient Discharge | 1 | 2016 | 770 | 0.090 |
Why?
| Phenotype | 2 | 2016 | 2858 | 0.090 |
Why?
| Cholesterol | 1 | 2011 | 367 | 0.090 |
Why?
| Longitudinal Studies | 1 | 2016 | 2437 | 0.090 |
Why?
| Triglycerides | 1 | 2011 | 470 | 0.090 |
Why?
| Kidney Failure, Chronic | 1 | 2015 | 491 | 0.090 |
Why?
| Leukocytes | 2 | 2012 | 284 | 0.080 |
Why?
| ATP-Binding Cassette Transporters | 1 | 2010 | 123 | 0.080 |
Why?
| Lipoproteins | 1 | 2010 | 162 | 0.080 |
Why?
| Risk Assessment | 3 | 2020 | 3004 | 0.080 |
Why?
| Surveys and Questionnaires | 1 | 2020 | 4670 | 0.080 |
Why?
| Databases, Factual | 3 | 2021 | 1149 | 0.080 |
Why?
| Incidence | 2 | 2020 | 2333 | 0.070 |
Why?
| Lung Diseases | 1 | 2014 | 710 | 0.070 |
Why?
| Weight Gain | 2 | 2021 | 454 | 0.070 |
Why?
| Drug Delivery Systems | 1 | 2010 | 301 | 0.070 |
Why?
| Pyrimidinones | 1 | 2007 | 86 | 0.070 |
Why?
| Indinavir | 1 | 2006 | 6 | 0.070 |
Why?
| Biomarkers | 3 | 2014 | 3473 | 0.070 |
Why?
| Reproducibility of Results | 1 | 2014 | 2814 | 0.070 |
Why?
| Linear Models | 2 | 2019 | 778 | 0.070 |
Why?
| Cost-Benefit Analysis | 2 | 2012 | 545 | 0.070 |
Why?
| Genetic Techniques | 1 | 2006 | 57 | 0.070 |
Why?
| Lamivudine | 1 | 2006 | 59 | 0.070 |
Why?
| Factor X | 1 | 2006 | 24 | 0.070 |
Why?
| Prothrombin | 1 | 2006 | 22 | 0.070 |
Why?
| Zidovudine | 1 | 2006 | 77 | 0.070 |
Why?
| Prognosis | 2 | 2014 | 3342 | 0.070 |
Why?
| Oxidation-Reduction | 1 | 2009 | 933 | 0.070 |
Why?
| Factor VII | 1 | 2006 | 26 | 0.070 |
Why?
| International Normalized Ratio | 1 | 2006 | 45 | 0.070 |
Why?
| Chemokines, CXC | 1 | 2006 | 58 | 0.070 |
Why?
| Drug Utilization | 1 | 2007 | 166 | 0.070 |
Why?
| C-Reactive Protein | 1 | 2008 | 364 | 0.070 |
Why?
| Base Sequence | 2 | 2006 | 2120 | 0.060 |
Why?
| Regression Analysis | 1 | 2008 | 961 | 0.060 |
Why?
| Delayed-Action Preparations | 1 | 2006 | 158 | 0.060 |
Why?
| Health Care Surveys | 1 | 2007 | 540 | 0.060 |
Why?
| Gene Expression Regulation | 1 | 2014 | 2362 | 0.060 |
Why?
| Mathematical Computing | 1 | 2004 | 12 | 0.060 |
Why?
| Risk Factors | 3 | 2020 | 8714 | 0.060 |
Why?
| Gene Expression | 1 | 2009 | 1442 | 0.060 |
Why?
| Drug Labeling | 1 | 2004 | 42 | 0.060 |
Why?
| Kidney | 2 | 2008 | 1208 | 0.060 |
Why?
| Infusions, Intravenous | 1 | 2004 | 374 | 0.060 |
Why?
| Laboratories | 1 | 2004 | 95 | 0.060 |
Why?
| Multidrug Resistance-Associated Proteins | 3 | 2008 | 36 | 0.060 |
Why?
| Socioeconomic Factors | 1 | 2007 | 1091 | 0.050 |
Why?
| Reference Values | 1 | 2004 | 745 | 0.050 |
Why?
| Linagliptin | 1 | 2021 | 4 | 0.050 |
Why?
| Adamantane | 1 | 2021 | 16 | 0.050 |
Why?
| Administrative Claims, Healthcare | 1 | 2021 | 21 | 0.050 |
Why?
| Dipeptides | 1 | 2021 | 49 | 0.050 |
Why?
| Electrocardiography | 1 | 2004 | 554 | 0.050 |
Why?
| Electronic Prescribing | 1 | 2021 | 4 | 0.050 |
Why?
| Uterine Hemorrhage | 1 | 2021 | 35 | 0.050 |
Why?
| Animals | 3 | 2008 | 32120 | 0.040 |
Why?
| Protective Factors | 1 | 2020 | 87 | 0.040 |
Why?
| Drug Tolerance | 1 | 2000 | 79 | 0.040 |
Why?
| Costs and Cost Analysis | 1 | 2020 | 200 | 0.040 |
Why?
| Treatment Failure | 1 | 2020 | 333 | 0.040 |
Why?
| Homozygote | 2 | 2012 | 186 | 0.040 |
Why?
| Kaplan-Meier Estimate | 1 | 2021 | 819 | 0.040 |
Why?
| Genomics | 1 | 2024 | 640 | 0.040 |
Why?
| Diabetes Mellitus | 1 | 2006 | 906 | 0.040 |
Why?
| Genetic Testing | 1 | 2021 | 385 | 0.040 |
Why?
| Antineoplastic Agents | 1 | 2009 | 1891 | 0.040 |
Why?
| Attitude | 1 | 2020 | 231 | 0.040 |
Why?
| Proportional Hazards Models | 1 | 2021 | 1088 | 0.040 |
Why?
| Glipizide | 1 | 2018 | 6 | 0.040 |
Why?
| Liver | 1 | 2006 | 1693 | 0.040 |
Why?
| Feasibility Studies | 1 | 2021 | 750 | 0.040 |
Why?
| Organic Anion Transport Protein 1 | 2 | 2008 | 6 | 0.040 |
Why?
| Glyburide | 1 | 2018 | 35 | 0.040 |
Why?
| Social Class | 1 | 2019 | 213 | 0.040 |
Why?
| Dexamethasone | 1 | 2000 | 315 | 0.040 |
Why?
| Self-Management | 1 | 2019 | 126 | 0.040 |
Why?
| Self Report | 1 | 2021 | 701 | 0.040 |
Why?
| Anesthetics | 1 | 2017 | 57 | 0.040 |
Why?
| Membrane Transport Proteins | 2 | 2008 | 137 | 0.030 |
Why?
| Tenofovir | 2 | 2008 | 205 | 0.030 |
Why?
| Peru | 1 | 2016 | 57 | 0.030 |
Why?
| Perioperative Care | 1 | 2017 | 127 | 0.030 |
Why?
| Cause of Death | 1 | 2018 | 369 | 0.030 |
Why?
| Pharmaceutical Services | 1 | 2016 | 79 | 0.030 |
Why?
| Medicaid | 1 | 2020 | 411 | 0.030 |
Why?
| Diabetic Angiopathies | 1 | 2018 | 243 | 0.030 |
Why?
| South Africa | 1 | 2016 | 162 | 0.030 |
Why?
| Indians, North American | 1 | 2021 | 593 | 0.030 |
Why?
| Alternative Splicing | 1 | 2017 | 186 | 0.030 |
Why?
| Preoperative Care | 1 | 2017 | 317 | 0.030 |
Why?
| HEK293 Cells | 1 | 2017 | 604 | 0.030 |
Why?
| Rats, Sprague-Dawley | 1 | 2000 | 2262 | 0.030 |
Why?
| Hepatitis C, Chronic | 1 | 2016 | 152 | 0.030 |
Why?
| Everolimus | 1 | 2014 | 63 | 0.030 |
Why?
| Receptors, Steroid | 1 | 2014 | 52 | 0.030 |
Why?
| Hypoglycemia | 1 | 2018 | 387 | 0.030 |
Why?
| Demography | 1 | 2014 | 264 | 0.030 |
Why?
| Mental Disorders | 1 | 2020 | 908 | 0.030 |
Why?
| Age Factors | 1 | 2019 | 2915 | 0.030 |
Why?
| Vasodilator Agents | 1 | 2014 | 308 | 0.030 |
Why?
| Heterozygote | 1 | 2012 | 254 | 0.020 |
Why?
| Rats | 1 | 2000 | 5035 | 0.020 |
Why?
| Genetic Loci | 1 | 2012 | 280 | 0.020 |
Why?
| Insulin | 1 | 2019 | 2083 | 0.020 |
Why?
| Critical Illness | 1 | 2015 | 646 | 0.020 |
Why?
| Algorithms | 2 | 2008 | 1493 | 0.020 |
Why?
| Body Composition | 1 | 2012 | 581 | 0.020 |
Why?
| Multivariate Analysis | 1 | 2012 | 1444 | 0.020 |
Why?
| Genetic Predisposition to Disease | 1 | 2017 | 2209 | 0.020 |
Why?
| Plasma | 1 | 2009 | 213 | 0.020 |
Why?
| Lopinavir | 1 | 2007 | 29 | 0.020 |
Why?
| PubMed | 1 | 2006 | 11 | 0.020 |
Why?
| Ribosomal Proteins | 1 | 2006 | 68 | 0.020 |
Why?
| Antiretroviral Therapy, Highly Active | 1 | 2007 | 257 | 0.020 |
Why?
| Pharmacology | 1 | 2005 | 8 | 0.020 |
Why?
| RNA, Messenger | 1 | 2012 | 2581 | 0.020 |
Why?
| Molecular Sequence Data | 1 | 2009 | 2793 | 0.020 |
Why?
| Likelihood Functions | 1 | 2005 | 131 | 0.020 |
Why?
| Mitochondrial Proteins | 1 | 2006 | 223 | 0.010 |
Why?
| Cardiotonic Agents | 1 | 2005 | 119 | 0.010 |
Why?
| Genome | 1 | 2006 | 266 | 0.010 |
Why?
| Hemorrhage | 1 | 2008 | 616 | 0.010 |
Why?
| Chromosome Mapping | 1 | 2005 | 502 | 0.010 |
Why?
| Drug Therapy, Combination | 1 | 2006 | 961 | 0.010 |
Why?
| Saccharomyces cerevisiae Proteins | 1 | 2006 | 337 | 0.010 |
Why?
| Predictive Value of Tests | 1 | 2008 | 1817 | 0.010 |
Why?
| Models, Genetic | 1 | 2005 | 584 | 0.010 |
Why?
| Pilot Projects | 1 | 2006 | 1374 | 0.010 |
Why?
| Child | 1 | 2020 | 18550 | 0.010 |
Why?
| Computer Simulation | 1 | 2005 | 887 | 0.010 |
Why?
| Case-Control Studies | 1 | 2007 | 3056 | 0.010 |
Why?
| Inflammation | 1 | 2006 | 2503 | 0.010 |
Why?
|
|
Aquilante's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|